DENALI THERAPEUTICS INC (DNLI) Fundamental Analysis & Valuation

NASDAQ:DNLI • US24823R1059

Current stock price

19.23 USD
-0.06 (-0.31%)
At close:
19.23 USD
0 (0%)
After Hours:

This DNLI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. DNLI Profitability Analysis

1.1 Basic Checks

  • DNLI had negative earnings in the past year.
  • DNLI had a negative operating cash flow in the past year.
  • DNLI had negative earnings in each of the past 5 years.
  • DNLI had a negative operating cash flow in each of the past 5 years.
DNLI Yearly Net Income VS EBIT VS OCF VS FCFDNLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M

1.2 Ratios

  • DNLI has a Return On Assets (-44.77%) which is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -50.56%, DNLI is in the better half of the industry, outperforming 61.70% of the companies in the same industry.
Industry RankSector Rank
ROA -44.77%
ROE -50.56%
ROIC N/A
ROA(3y)-29.37%
ROA(5y)-26.23%
ROE(3y)-33.01%
ROE(5y)-32.1%
ROIC(3y)N/A
ROIC(5y)N/A
DNLI Yearly ROA, ROE, ROICDNLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30 -40 -50

1.3 Margins

  • DNLI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNLI Yearly Profit, Operating, Gross MarginsDNLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. DNLI Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, DNLI has more shares outstanding
  • DNLI has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for DNLI has been reduced compared to a year ago.
DNLI Yearly Shares OutstandingDNLI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
DNLI Yearly Total Debt VS Total AssetsDNLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • DNLI has an Altman-Z score of 10.69. This indicates that DNLI is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of DNLI (10.69) is better than 82.20% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that DNLI is not too dependend on debt financing.
  • DNLI has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: DNLI outperforms 47.39% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 10.69
ROIC/WACCN/A
WACCN/A
DNLI Yearly LT Debt VS Equity VS FCFDNLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 9.16 indicates that DNLI has no problem at all paying its short term obligations.
  • DNLI has a Current ratio of 9.16. This is in the better half of the industry: DNLI outperforms 76.98% of its industry peers.
  • DNLI has a Quick Ratio of 9.16. This indicates that DNLI is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 9.16, DNLI is doing good in the industry, outperforming 76.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.16
Quick Ratio 9.16
DNLI Yearly Current Assets VS Current LiabilitesDNLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. DNLI Growth Analysis

3.1 Past

  • DNLI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.24%.
EPS 1Y (TTM)-11.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 20.63% on average over the next years. This is a very strong growth
  • DNLI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 309.60% yearly.
EPS Next Y7.09%
EPS Next 2Y7.19%
EPS Next 3Y18.22%
EPS Next 5Y20.63%
Revenue Next Year2533.63%
Revenue Next 2Y1097.51%
Revenue Next 3Y663.89%
Revenue Next 5Y309.6%

3.3 Evolution

DNLI Yearly Revenue VS EstimatesDNLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
DNLI Yearly EPS VS EstimatesDNLI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. DNLI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DNLI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNLI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNLI Price Earnings VS Forward Price EarningsDNLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNLI Per share dataDNLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • DNLI's earnings are expected to grow with 18.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.19%
EPS Next 3Y18.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DNLI Dividend Analysis

5.1 Amount

  • No dividends for DNLI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DNLI Fundamentals: All Metrics, Ratios and Statistics

DENALI THERAPEUTICS INC

NASDAQ:DNLI (4/10/2026, 8:17:44 PM)

After market: 19.23 0 (0%)

19.23

-0.06 (-0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-04
Inst Owners97.49%
Inst Owner Change0%
Ins Owners4.26%
Ins Owner Change0.69%
Market Cap3.05B
Revenue(TTM)N/A
Net Income(TTM)-512.54M
Analysts87.2
Price Target36.52 (89.91%)
Short Float %9.96%
Short Ratio7.73
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.66%
Min EPS beat(2)3.5%
Max EPS beat(2)3.82%
EPS beat(4)3
Avg EPS beat(4)-0.56%
Min EPS beat(4)-11.43%
Max EPS beat(4)3.82%
EPS beat(8)5
Avg EPS beat(8)2.79%
EPS beat(12)7
Avg EPS beat(12)25.38%
EPS beat(16)9
Avg EPS beat(16)20.08%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.81%
PT rev (3m)12.42%
EPS NQ rev (1m)1.02%
EPS NQ rev (3m)7.31%
EPS NY rev (1m)3.07%
EPS NY rev (3m)7.37%
Revenue NQ rev (1m)2.51%
Revenue NQ rev (3m)-71.34%
Revenue NY rev (1m)-31.81%
Revenue NY rev (3m)-39.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.01
P/tB 3.01
EV/EBITDA N/A
EPS(TTM)-2.97
EYN/A
EPS(NY)-2.76
Fwd EYN/A
FCF(TTM)-2.66
FCFYN/A
OCF(TTM)-2.6
OCFYN/A
SpS0
BVpS6.39
TBVpS6.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.77%
ROE -50.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.37%
ROA(5y)-26.23%
ROE(3y)-33.01%
ROE(5y)-32.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.16
Quick Ratio 9.16
Altman-Z 10.69
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.16%
Cap/Depr(5y)117.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.96%
EPS Next Y7.09%
EPS Next 2Y7.19%
EPS Next 3Y18.22%
EPS Next 5Y20.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year2533.63%
Revenue Next 2Y1097.51%
Revenue Next 3Y663.89%
Revenue Next 5Y309.6%
EBIT growth 1Y-10.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.35%
EBIT Next 3Y13.79%
EBIT Next 5Y29.39%
FCF growth 1Y-16.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.67%
OCF growth 3YN/A
OCF growth 5YN/A

DENALI THERAPEUTICS INC / DNLI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of DENALI THERAPEUTICS INC (DNLI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DNLI.


Can you provide the valuation status for DENALI THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to DENALI THERAPEUTICS INC (DNLI). This can be considered as Overvalued.


Can you provide the profitability details for DENALI THERAPEUTICS INC?

DENALI THERAPEUTICS INC (DNLI) has a profitability rating of 1 / 10.


What is the financial health of DENALI THERAPEUTICS INC (DNLI) stock?

The financial health rating of DENALI THERAPEUTICS INC (DNLI) is 5 / 10.


What is the earnings growth outlook for DENALI THERAPEUTICS INC?

The Earnings per Share (EPS) of DENALI THERAPEUTICS INC (DNLI) is expected to grow by 7.09% in the next year.